0.68 - 0.75
0.33 - 0.86
18.36M / 4.66M (Avg.)
34.50 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.54%
Revenue growth under 50% of 0259.HK's 19.03%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-15.02%
Negative gross profit growth while 0259.HK is at 17.71%. Joel Greenblatt would examine cost competitiveness or demand decline.
-30.53%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-30.53%
Negative operating income growth while 0259.HK is at 11.17%. Joel Greenblatt would press for urgent turnaround measures.
2.50%
Net income growth above 1.5x 0259.HK's 0.36%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
0.99%
EPS growth above 1.5x 0259.HK's 0.39%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
-4.19%
Negative diluted EPS growth while 0259.HK is at 0.39%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1.44%
Share count expansion well above 0259.HK's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.00%
Diluted share change of 7.00% while 0259.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
39.94%
Positive OCF growth while 0259.HK is negative. John Neff would see this as a clear operational advantage vs. the competitor.
37.76%
Positive FCF growth while 0259.HK is negative. John Neff would see a strong competitive edge in net cash generation.
247.66%
10Y revenue/share CAGR above 1.5x 0259.HK's 135.53%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
19.94%
5Y revenue/share CAGR under 50% of 0259.HK's 40.40%. Michael Burry would suspect a significant competitive gap or product weakness.
-10.19%
Negative 3Y CAGR while 0259.HK stands at 11.58%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-6520.63%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-394.38%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-261.16%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
17.38%
Below 50% of 0259.HK's 527.03%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
27.23%
Below 50% of 0259.HK's 65.94%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
59.09%
3Y net income/share CAGR above 1.5x 0259.HK's 21.23%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
97.28%
Positive 5Y equity/share CAGR while 0259.HK is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
6.65%
Below 50% of 0259.HK's 57.37%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
578.71%
5Y dividend/share CAGR above 1.5x 0259.HK's 140.00%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
120.50%
3Y dividend/share CAGR 1.25-1.5x 0259.HK's 100.00%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
44.39%
AR growth well above 0259.HK's 31.22%. Michael Burry fears inflated revenue or higher default risk in the near future.
-44.69%
Inventory is declining while 0259.HK stands at 16.33%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
14.57%
Asset growth above 1.5x 0259.HK's 8.70%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
2.88%
50-75% of 0259.HK's 4.42%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
206.46%
We have some new debt while 0259.HK reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-36.19%
Our R&D shrinks while 0259.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.02%
We cut SG&A while 0259.HK invests at 22.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.